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Background: Lesch-Nyhan disease is a rare X-linked neurodevelopemental metabolic disorder caused by a wide
variety of mutations in the HPRT1 gene leading to a deficiency of the purine recycling enzyme hypoxanthine-guanine
phosphoribosyltransferase (HGprt). The residual HGprt activity correlates with the various phenotypes of Lesch-Nyhan
(LN) patients and in particular with the different degree of neurobehavioral disturbances. The prevalence of this
disease is considered to be underestimated due to large heterogeneity of its clinical symptoms and the difficulty of
diagnosing of the less severe forms of the disease. We therefore searched for metabolic changes that would facilitate
an early diagnosis and give potential clues on the disease pathogenesis and potential therapeutic approaches.
Methods: Lesch-Nyhan patients were diagnosed using HGprt enzymatic assay in red blood cells and identification of
the causal HPRT1 gene mutations. These patients were subsequently classified into the three main phenotypic
subgroups ranging from patients with only hyperuricemia to individuals presenting motor dysfunction, cognitive
disability and self-injurious behavior. Metabolites from the three classes of patients were analyzed and quantified by High
Performance Ionic Chromatography and biomarkers of HGprt deficiency were then validated by statistical analyses.
Results: A cohort of 139 patients, from 112 families, diagnosed using HGprt enzymatic assay in red blood cells, was
studied. 98 displayed LN full phenotype (86 families) and 41 (26 families) had attenuated clinical phenotypes.
Genotype/phenotype correlations show that LN full phenotype was correlated to genetic alterations resulting in null
enzyme function, while variant phenotypes are often associated with missense mutations allowing some residual
HGprt activity. Analysis of metabolites extracted from red blood cells from 56 LN patients revealed strong variations
specific to HGprt deficiency for six metabolites (AICAR mono- and tri-phosphate, nicotinamide, nicotinic acid, ATP
and Succinyl-AMP) as compared to controls including hyperuricemic patients without HGprt deficiency.
Conclusions: A highly significant correlation between six metabolites and the HGprt deficiency was established,
each of them providing an easily measurable marker of the disease. Their combination strongly increases the
probability of an early and reliable diagnosis for HGprt deficiency.
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The ubiquitous distribution of purine derivatives in hu-
man tissues and the high number of cellular functions in
which these metabolites are involved explain why purine
metabolism impairments lead to so many various diseases,
i.e. >35 genetic pathologies are associated to purine me-
tabolism genes (see [1] for review). The early recognition
of these patients is required because of the progressive, ir-
reversible and devastating consequences of these deficien-
cies [2]. A lot of these purine-associated pathologies share
neurological, muscular, hematological and immunological
symptoms. These common symptoms are most likely the
consequence of nucleotide depletion and/or accumulation
of toxic intermediates altering various biological functions,
many of these deleterious effects taking place during em-
bryonic development. Yet, the molecular mechanisms
leading to these alterations are largely unknown and re-
main to be identified.
Among purine-metabolism pathologies, the Lesch-Nyhan
(LN) disease is a rare X-linked genetic disease, character-
ized in the most severe form by overproduction of uric acid,
gout, severe motor disability, neurological deficiency and
self-injurious behavior [3-5]. Milder forms of the disease,
named Lesch-Nyhan Variants (LNV), exhibit less pro-
nounced neurological and/or motor impairments and no
self-injurious behavior [6-10]. A single mutated gene,
HPRT1, is responsible for the LN pathology. HPRT1 en-
codes the Hypoxanthine/Guanine phosphorybosyl transfer-
ase enzyme HGprt involved in two steps of the purine
salvage pathway, i.e. conversion of hypoxanthine andPRPP
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monophosphate (GMP), respectively (Figure 1). The mu-
tations are highly heterogeneous, with more than 400 dif-
ferent mutations already documented (http://www.lesch-
nyhan.org/en/research/mutations-database/). Depending
on the mutation, the enzyme exhibits none or residual
enzymatic activity. Residual activity correlates with the
severity of symptoms and in particular with the degree of
neurological disturbances [3,11]. Hence, a phenotypic
classification in three groups has now been accepted
[3,4,9]. Lesch-Nyhan Disease (LND) patients display
neurological deficiencies and self-injurious behaviors;
they usually have undetectable HGprt activity. A second
set of patients with various degrees of neuromuscular
symptoms but no self-injurious behavior were grouped in
HND (HGprt-related Neurological Dysfunction), they
typically have a residual HGprt activity in live fibroblast
assay. Finally, a third group of patients presenting no neu-
robehavioral disturbances and symptoms secondary to hy-
peruricemia only were classified as HRH (HGprt-Related
Hyperuricemia) and generally have an enzymatic activity
above 10%. Despite this correlation between enzymatic ac-
tivity in live fibroblast and neurological disturbances, the
underlying molecular mechanisms responsible for neurobe-
havioral troubles remain unknown. HGprt deficiency might
affect homeostasis of purine metabolites, some of which
play critical roles in neuronal differentiation and function
and are toxic for the brain. Studies have shown that neuro-
behavioral syndrome is linked to reduction of dopamine in
the basal ganglia [12] and demonstrated that HGprtR
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pathways involved in the development of dopaminergic
neurons [13-15]. The lack of a functional purine salvage
pathway causes purine limitation in both undifferentiated
and differentiated cells, as well as profound loss of dopa-
mine content [16]. These results imply an unknown
mechanism by which intracellular purine level modulates
dopamine level.
In this study, we took advantage of a large cohort of
139 French patients to statistically evaluate the relation-
ship between phenotype/genotype and purine, pyrimi-
dine and pyridine content of red blood cells. Our aim
was first to identify new biological markers to facilitate
diagnosis of Lesch-Nyhan patients and second to pro-
vide clues on future therapy quests.
Methods
Patients and their classification
From 1980 to 2014, 139 patients from 112 families were
diagnosed in our laboratory (I.C.P) using HGprt enzym-
atic assay in red blood cells. Clinical examination and
HGprt dosage revealed 98 patients with the severe LND
phenotype (86 families) and 41 LN variants (26 families)
with attenuated symptoms. Lesch-Nyhan patients were
thereafter classified according to prior validated pheno-
typic classification [4,9,17,18]. Briefly, in this cohort, 98
LND patients (in 86 families) with a full phenotype pre-
sented overproduction of uric acid, gout, severe motor
disability, neurological deficiency and self-injurious be-
havior. Among LN variants, those presenting varying de-
gree of neuromuscular symptoms but no self-injurious
behavior (26 patients in 18 families) were grouped as
HND, while 14 patients in 8 families with no neurobe-
havioral disturbances were grouped as HRH.
Statement of ethical approval
The patient DNA and red blood cells collections used in
this study were declared (N° DC-2009-955) at the “Plate-
forme de Ressources Biologiques” from Necker Univer-
sity Hospital (Paris; France) primarily for diagnosis and
re-qualified for research purpose with the written con-
sent of each patient or their parents.
Mutation of HPRT1
The sequencing analysis was performed on 85 patients
from 65 families among the 112 families of the French
registry. A legal informed consent was obtained from all
patients. Molecular analysis of the HPRT1 gene was per-
formed on genomic DNA from LND (n = 54 in 47 fam-
ilies), HND (n = 19 in 12 families) and HRH (n = 12 in 6
families) patients isolated from whole blood, as previ-
ously described by [7]. Briefly, the PCR primers used for
exons 1–9 allowed genomic sequence analyses of both
intron and exon segments involved in splice sequencemutations. All 9 exons of the HPRT1 gene were ampli-
fied on 8 separate DNA fragments, with different
lengths, using the kit AccuPrime GC rich for exon 1
and the kit Platinum Pfx for exons 2–9 (Invitrogen,
Carlsbad, CA). The amplified fragments were purified
using Illumina Exostar (Illumina) and sequenced using
the same primers.
Metabolic analyses
All metabolite extractions were performed on the blood
samples used for the clinical diagnosis of patients. Metab-
olite extraction was achieved by boiling 100 μl of red
blood cells in 5 ml of an ethanol/HEPES 10 mM pH 7.2
(3/1) solution for 3 min at 80°C. Samples were evaporated
using a rotavapor apparatus (8 min, 65°C) and the dried
residue was resuspended in 500 μl of MilliQ water. Insol-
uble particles were removed by centrifugation (21,000 g,
4°C, 1 hour) and the supernatant was ultra-filtrated on
nanosep10K Omega (Pall). Metabolites were then sepa-
rated on an ICS3000 chromatography station (Dionex,
Sunnyvale, USA) using a carbopac PA1 column (250 ×
2 mm; Dionex) with a 0.25 ml/min flow. Elution of me-
tabolites was achieved with a Na-Acetate (NaAc) gradient
in 50 mM NaOH as follows: elution was started at
50 mM NaAc for 2 min, rising up to 75 mM in 8 min,
then to 100 mM in 25 min and finally to 350 mM in
30 min, followed by a step at 350 mM for 5 min, rising to
500 mM in 10 min, kept at this Na-Ac concentration for
5 min and finally raised up to 800 mM in 10 min followed
by a step at this concentration for 20 min. The resin was
then equilibrated at 50 mM NaAc for 15 min before injec-
tion of a new sample. Peaks were identified by their reten-
tion time and their UV spectrum signature (Diode Array
Detector Ultimate 3000 RS, Dionex) and when necessary
by co-injection with standards. When sufficient blood
samples were available, metabolic analyses were per-
formed on two independent metabolite extractions from
patient’s red blood cells. The following metabolite sam-
ples were obtained and analyzed: 32 samples from
asymptomatic patients (48 independent extracts); 29
samples from LND patients (47 independent extracts); 15
samples from HND patients (23 independent extracts);
12 samples from HRH patients (21 independent extracts);
13 samples from non Lesch-Nyhan patients presenting
hyperuricemia (25 independent extracts). Metabolite
amounts were normalized to hemoglobin content in the
red blood cell samples measured spectrophotometrically
(546 nm) using the Drabkin’s colorimetric reagent (5 ml;
Chem-Lab NV, Belgium) on 20 μl of red blood cells sam-
ples. Of note, the metabolic extractions were done on red
blood cells kept frozen at −20°C since the blood sam-
pling. Statistical analyses revealed no significant correl-
ation between any metabolic variation and the duration
of freezing.
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Qualitative data were described by the sample size and
percentage of each variable class. For quantitative data, we
used quartile based indices (median, first-third quartile,
min-max) to summarize variables and Wilcoxon rank-
sum test to perform group comparisons. To summarize
informative value of each metabolite as a diagnostic bio-
marker, we computed the area under the curve of the
Receiver Operating Curve (AUC-ROC) [19]. Briefly AUC-
ROC evaluates the ability of a quantitative marker to dis-
criminate between two groups (for example patients and
controls), a value of 1 indicates a perfect discrimination
and 0.5 a complete absence of discrimination. If we enu-
merate all possible patient-control pairs, AUC-ROC can
also be interpreted as the percentage of correctly ordered
pairs, i.e. pairs where the patient marker level is higher
than the control one, if the marker is expected to be in-
creased in patients, and reciprocally if the marker is ex-
pected to be higher in controls. All computations were
performed with the R statistical package v2.5 (http://www.
r-project.org/). For the ROC analyses, we used the R
ROCR library [20]. All tests were performed using a bilat-
eral formulation. P-values less than 5% were considered as
statistically significant. All metabolic distributions and
ROC curves were drawn using Graph-Pad Prism software.
Results and discussion
Genotype/Phenotype classification of full LND and LN
Variants
The French cohort of Lesch-Nyhan patients was split
into the three approved sub-groups [3] depending on the
degree of neurological disturbances, from none to severe:
HRH, HND, LND. It should be stressed that the average
diagnosis age of the patient of the 3 groups varies signifi-
cantly due to the obviousness of the most severe symp-
toms (Figure 2A). Sequencing analysis of the HPRT1
gene revealed 61 different mutations among these 85 pa-
tients, spanning 65 families, 27 of which were novel. Of
note, all these mutations including the 27 newly identi-
fied are listed in http://www.lesch-nyhan.org/en/re-
search/mutations-database/. While the nature of the
mutations was clearly not evenly distributed in the three
groups (Figure 2B), we found that the location of the mu-
tation was not a good prognostic marker of the severity
of the disease (Figure 2C). The mutations were indeed
scattered along the gene and no hot clusters were identi-
fied. This shows that multiple mutations of HPRT1 can
cause the unique Lesch-Nyhan disease. Within the LND
group, 54 Lesch-Nyhan patients, spanning 47 families
were analyzed. We found 45 different mutations distrib-
uted throughout the gene. For the Variants a total of 16
mutations were found in 19 HND patients (12 families)
and in 12 HRH patients (6 families). Importantly, in
LND, only 32% of mutations are missense, while 68% ofthe mutations were deletion, insertion, nonsense and
splicing mutations (Figure 2B). Approximately half of the
deletions were large intragenic deletions with loss of one
or more exons. All mutations in introns gave rise to spli-
cing error mutations and to LND. For the Variant forms
HND and HRH, this tendency is completely reversed
with a majority of missense mutations (88%) and the
quasi-absence of deletion, nonsense and splicing muta-
tions (Figure 2B). The difference in the type of mutations
between LND and Variants suggests that mutations more
susceptible to result in null enzymatic function or in ab-
normal protein conformation are more likely to cause
the severe phenotype LND. By contrast, in the Variant
forms, the missense mutations may allow some residual
activity of the protein leading to a less severe phenotype.
Identification of new biochemical markers for diagnosis
of HGprt deficiency
Blood samples from patients and controls were used to
measure intracellular metabolite content in red blood
cells. Because LND affects purine metabolism, we moni-
tored the level of purine nucleotides, nucleosides and
bases. In the same separation experiment we also mea-
sured pyrimidine nucleotides, nucleosides and bases as
well as NAD(H) (Nicotinamide adenine di-nucleotide)
and their precursors (Figure 3A). A comparison of rep-
resentative chromatograms obtained with red blood cell
extracts from a control and a HRH patient is presented
in Figure 3B. Of note, GMP one of the products of
HGprt (Figure 1) is not detectable in any control or
Lesch-Nyhan patient red blood extracts. This observa-
tion is consistent with a previous one in which the pres-
ence of only the di- and tri-phosphate forms of guanylic
nucleotides were detected in patient erythrocytes [21].
For each metabolite analyzed, statistical analyses of the
data were conducted by drawing ROC (Receiving Oper-
ating Characteristic) curves and deducing the cognate
AUC (Area Under Curve, see Methods for details). For
eight metabolites the AUC were comprised between 0.8
and 1 (Figure 4A and Additional file 1: Figure S1) indi-
cating a fair to excellent accuracy of the test in discrim-
inating the groups being tested. Ten other metabolites
presented some apparent differences between the con-
trol and LN patients, but statistical analyses revealed
that for these metabolites AUC were between 0.80 and
0.5 and therefore had low or no significance (Additional
file 1: Figure S2). Among the eight metabolites, signifi-
cantly discriminating Lesch-Nyhan patients versus con-
trols, are five purine derivatives (AICAR, hypoxanthine,
ZTP (triphosphate form of AICAR), ATP and S-AMP),
one pyrimidine (UMP) and precursors of NAD(H) (nico-
tinic acid and nicotinamide and/or nicotinamide riboside,
these two last metabolites cannot be discriminated under
our separation conditions). Importantly, some of these
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Figure 2 Genotypic characterization of the French cohort of Lesch-Nyhan patients. A) Average diagnosis age of the patient as function of
symptoms severity. The median age is represented by the thick black line: HRH: HGprt-related Hyperuricemia (Median age 25 years old). HND:
HGprt-related hyperuricemia with neuro-muscular dysfunction (Median age 18 years old). LND: full Lesch-Nyhan disease (Median age 3 years old).
B) Distribution of mutation types throughout the HPRT1 gene among the three groups of HGprt deficient patients. Black, blue and orange boxes
represent mutations in LND, HND and HRH patients, respectively. C) Localization of the mutations on the HPRT1 gene in the French cohort of LN
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lem rather than being “specific” to HGprt deficiency. We
therefore performed a similar metabolic analysis from
blood samples from 13 hyperuricemic patients presenting
normal HGprt activity (Figure 4 and Additional file 1:
Table S1). In these patients two of the eight markers, i.e.
hypoxanthine and UMP, were also accumulated in red
blood cells (statistical results, Figure 4B and E), thus sug-
gesting that hypoxanthine and UMP changes are more as-
sociated to hyperuricemia than to HGprt deficiency. In
addition, while five of the thirteen hyperuricemic patients
were treated with xanthine oxydoreductase inhibitor Allo-
purinol (Additional file 1: Table S1), we did not find any
statistically significant difference on metabolites between
treated and non-treated patients. From these analyses, we
conclude that six metabolites significantly discriminate be-
tween HGprt deficient patients and healthy controls. Wealso performed a non parametric correlation analysis to
determine is these six metabolites associated with HGprt
deficiency could serve as biomarker of Lesch-Nyhan dis-
ease at any age of patients. For five of them (AICAR, ZTP,
nicotinamide (riboside), ATP and S-AMP) we found no
influence of age on the statistical relevance (p > 0.13, non-
statistical significant correlation with age of patient for
any of these metabolites) of using these metabolites as
biomarkers for Lesch-Nyhan diagnosis. By contrast, for
nicotinic acid, we found that strength of the biomarker
significantly (p = 0.005, statistical significance **) decreases
with age of the patient and is even not statistically signifi-
cant for patients over 50 years old. Nevertheless, for these
older patients the five other biomarkers are still fully sta-
tistically relevant for diagnosis of Lesch-Nyhan disease.
Among the six the metabolites, AICAR and ZTP, have
very high AUC (0.99 and 0.92 respectively, Figure 4A
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highly predictive biochemical markers. Accumulation of
ZTP in LN patients has been reported previously on a
small number of patients (5 LND + 1 LN variant) [21].
Our statistical analysis on a much larger cohort of LN pa-
tients definitely validates this biomarker. It should be
stressed however that AICAR and ZTP accumulationshave been reported in few patients with other purine
metabolic disorders: purine nucleoside phosphorylase de-
ficiency (Pnp; 1 patient), phosphorybosyl pyrophosphate
(PRPP) synthetase over-activity (1 patient), and AICAR
transformylase IMP cyclohydrolase deficiency (Atic, 1 pa-
tient) [21,22] and therefore could not be fully discrimina-
tive for diagnosis. Nonetheless, the combination of these
Ceballos-Picot et al. Orphanet Journal of Rare Diseases  (2015) 10:7 Page 8 of 11two AICAR derivatives with the four other identified bio-
markers with high AUC strongly increases the prognostic
power. Importantly, our metabolic analysis was done on
red blood cells which are prone to accumulate AICAR
[23] and therefore amplifies this metabolic signal. Indeed,
AICAR accumulation was not detected on patient fibro-
blasts (I.C.P. and B.P. unpublished results). It thus appears
that red blood cells, which are easy to collect, are also
providentially propitious to the use of these biomarkers.
Of note, one could expect that alteration of HGprt activity
in LN patients lead to a decrease in IMP pool, but
we found no significant difference in IMP content be-
tween LN patients and healthy controls (Additional file 1:
Figure S2). One possible explanation for this is that, in
erythrocytes, AICAR is used as a precursor of a metabolic
bypass that can replenish the IMP pool in a HGprt-
deficient context (Figure 1) [24].
To address the role of HGprt in the pathogenesis of
LND, several in vitro studies have been already per-
formed comparing nucleotide metabolism in different
cell types (lymphoblast and fibroblasts) from LND pa-
tients versus subjects with normal HGprt activity, or tis-
sue/cell lines from HPRT1 gene knock-out (KO) mice.
The results were rather inconsistent [25-28]. Contribut-
ing factors to explain such variations have included cul-
ture conditions, unappreciated differences in growth
rates and variability in precursor concentrations (e.g.
nicotinamide) in different culture conditions [26,27,29].
Here, the analysis of erythrocytes, a single cell type dir-
ectly sampled from patients, allowed to bypass these
problems. Some of these earlier studies documented al-
tered pyridine and purine nucleotide metabolite content
in LND erythrocytes showing elevated NAD(H), as well
as low GTP and ATP concentrations [30]. In addition,
studies of NAD(H) metabolism on different tissues from
HGprt gene knock-out (KO) mice revealed that NAD+
concentration was significantly increased in liver but not
in brain or blood of the KO mice [31]. By contrast, NAD+
was found severely decreased in fibroblast from Lesch-
Nyhan patients [29]. These results and ours demonstrate
that changes in NAD(H) metabolism occur in response to
HGprt deficiency, depending both on species and tissue
type, however the physiopathological consequences re-
main to be explored.
Correlation of metabolic profiles with clinical severity
Our results presented in the previous section established
that the metabolic profile of patients significantly dif-
fered from that of controls and from that of non-LND
gouty patients indicating that beyond the HGprt defi-
ciency resides a more complex metabolic disease. We
then investigated whether the six biochemical markers
identified in this study could be used to assess the sever-
ity of the disease. We found that this was clearly not thecase since statistical analyses showed no significant dif-
ferences for the six biomarkers between the different
classes of patients (Figure 5 A to F). However, it should
be emphasized that for the two most severe forms of the
disease (LND and HND) self-injurious behaviors and/or
neuromuscular symptoms are easily diagnosed and the
biomarkers in these cases could mostly be used for con-
firmation together with HGprt activity measurement.
For the last group of patients suffering from hyperurice-
mia but presenting no neurobehavioral disturbances,
HRH group, diagnosis often happens much later during
life, frequently in adulthood (see Figure 2A). For these
cases, the biochemical markers described here will be
very useful to facilitate diagnosis at an early stage of the
disease. The usefulness of these biomarkers would be
further amplified if systematic search for hyperuricemia
at birth was envisioned.
Why is there no clear correlation between the purine
and pyrimidine metabolic profiles and the severity of the
disease? A likely possibility is that the metabolic profiles,
being derived from red blood cells of children or adults,
does not fully reflect what happens in other cell types (es-
pecially neural tissues) and/or during embryonic develop-
ment. A general question about the biomarkers identified
in this study is whether they could be causative of some
aspects of the pathology, as it was previously hypothe-
sized concerning AICAR accumulation and the potential
toxicity of this metabolite [32]. Massive accumulation of
AICAR and its derivatives in Atic deficiency is associated
with a devastating neurological disease involving pro-
found mental retardation, epilepsy, dysmorphic features
and congenital blindness [22]. In addition, AICAR is an
inhibitor of the bi-functional enzyme Adenylosuccinate
lyase (Adsl; Figure 1) and a deficiency of this enzyme also
causes psychomotor retardation and autism in humans
[33]. Indeed, the significant increase of succinyl-AMP
(Figure 4H) in red blood cells of LN patients is in favor
of a possible inhibition by AICAR of Adsl. AICAR, be-
cause of its structural similarity with AMP [34], is also a
known activator of the AMP-activated protein kinase
(AMPK), a homeostatic regulator of energy levels in the
cell and influences the activity of a number of AMP-
sensitive enzymes [35]. Accumulation of AICAR could
have pleiotropic effects in the brain that could explain
some of the neurological symptoms of Lesch-Nyhan pa-
tients. To establish a possible correlative link between
AICAR accumulation and the severity of neurological
symptoms in Lesch-Nyhan patients, metabolic analyses
on cerebrospinal fluid would be more conclusive; how-
ever this biological material is not generally available. Of
note, despite these difficulties, we could measure meta-
bolic content in cerebrospinal fluid of few LND patients
(8 patients) and healthy controls (6 patients). Even
though purine derivatives were at very low concentration
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Figure 5 Changes in identified biomarkers are not correlated with severity of the disease. (A-F) For all categories, each dot corresponds to
the mean of metabolite content measured in independent red blood cells extracts. AUC values (green numbers) correspond to Area Under
Curves values deduced from ROC analyses performed as described in methods. p-values were obtained from a Mann–Whitney–Wilcoxon test: NS:
non-statistically different = p-value > 10−1. Control: healthy patients (black circles); HRH: HGprt-related hyperuricemia (orange squares); HND:
HGprt-related hyperuricemia with neuromuscular dysfunction (blue squares); LND: full Lesch-Nyhan disease (green squares).
Ceballos-Picot et al. Orphanet Journal of Rare Diseases  (2015) 10:7 Page 9 of 11in these samples, we found some AICAR in its riboside
form (AICAr) in Lesch-Nyhan patient cerebrospinal fluid
but not in the controls (I.C-P. and B.P. unpublished
results).
Our analysis on the LND patient erythrocytes also
showed that the ATP concentration was significantly
lower when compared to healthy control and/or gouty pa-
tients, as already observed by others [36]. A significant de-
crease in GTP concentration was also found (AUC 0.74,
Additional file 1: Figure S2), thus confirming previous
in vitro results obtained on human neuronal tissue cul-
ture [37]. The combined ATP and GTP depletion inerythrocytes could reflect the situation in the brain, which,
like the erythrocyte, is largely dependent on salvage path-
ways to sustain its ATP and GTP levels. Because ATP is a
downstream product of purine metabolism, HGprt defi-
ciency results in energy limitation. Present knowledge as-
sumes that defective dopaminergic transmission is an
important cause for neurological deficit in LND [12], how-
ever the mechanisms responsible for dopamine loss in
HGprt deficiency is still an enigma. Shortage of specific
nucleotides may cause this abnormality through the inhib-
ition of nigrostriatal axonal arborization at a developmen-
tal stage sensitive to nucleotide availability [13,14].
Ceballos-Picot et al. Orphanet Journal of Rare Diseases  (2015) 10:7 Page 10 of 11Conclusion
We documented the molecular and biochemical analysis
of Lesch-Nyhan disease in a large cohort of 139 patients
from France belonging to 112 unrelated families. Se-
quence analysis of the HPRT1 gene revealed that muta-
tions were scattered along the gene and no hot clusters
were identified. Importantly, within the most severe
phenotypic group (LND) 68% of the mutations were de-
letion, insertion, nonsense and splicing mutations,
mostly resulting in undetectable enzyme function. In
Variant forms, HND and HRH, this tendency is com-
pletely reversed with a majority of missense mutations
(88%), thus leading to residual HGprt activity. The effect
of the HPRT1 mutations on residual HGprt enzyme ac-
tivity is a relevant factor contributing to disease pheno-
type. Diversity of inborn errors in nucleotide metabolism
leading to a large spectrum of common neurodevelope-
mental symptoms makes the diagnosis difficult, especially
for patients with the less severe forms of these various
diseases. Our chromatographic method allowed us to
identify six metabolites (dramatic increase for AICAR,
ZTP, nicotinic acid, nicotinamide (riboside), S-AMP and
severe ATP depletion) statistically fully associated to
HGprt deficiency. These six metabolites define new spe-
cific biomarkers since they are not significantly modified
in hyperuricemic patients without HGprt-deficiency.
These new biochemical markers are easy to measure on
red blood cell extracts and their combination increases
the probability of an early and reliable diagnose of less se-
vere forms of HGprt deficiency.Additional file
Additional file 1: Figure S1. Representation of Receiver Operating
Curve used to calculate AUC (Area Under Curves). The Receiver Operating
Curves were obtained as described in methods. “Sensitivity” (also called
the true positive rate) represents the percentage of sick people who are
correctly identified, while “Specificity” (also called the true negative rate)
measures the proportion of healthy people correctly identified. A perfect
metabolic marker would be described as 100% sensitivity (i.e. predicting
all people from the sick group as sick) and 100% specificity (i.e. not
predicting anyone from the control group as sick) thus leading to an
AUC = 1. By contrast, a non discriminative metabolite would be found
with an AUC close to 0.5. Dashed black diagonal represents the line of
identity between the two groups. Figure S2. Other metabolic changes in
red blood cells from HGprt deficient patients. For all categories, each dot
corresponds to the mean of metabolite content measured in
independent red blood cells extracts. AUC values (green numbers)
correspond to Area Under Curves values deduced from ROC analyses
performed as described in Methods. p-values were obtained from a
Mann–Whitney–Wilcoxon test: NS: non-statistically different = p-value >
10−1; *: p-value < 10−2; **: p-value < 10−3 and ***: p-value < 10−4. Control:
healthy patients (black circles); LN: Lesch-Nyhan patients (HRH + HND +
LND; Red squares); Non-HGprt: non HGprt-deficient patients with
hyperuricemia (blue diamonds). Table S1. Values are given in μmol
metabolite/mmol Hemoglobin.Competing interests
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